No Data
No Data
Jefferies Maintains Kezar Life Sciences(KZR.US) With Buy Rating, Cuts Target Price to $18
Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating
Kezar Life Sciences Price Target Lowered to $7 From $9 at Wells Fargo
Analysts' Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)
Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences
Kezar Drops After Q4 Results and Mid-stage Data for Lead Asset